#USA #Robbins Geller #San Diego #Class Action #MoonLake

MoonLake Immunotherapeutics and the Class Action Landscape

In recent news, MoonLake Immunotherapeutics, a clinical stage biotechnology company, has found itself at the center of a potential legal storm. Investors who have sustained notable losses are now presented with the opportunity to lead a class action lawsuit against the firm. The action is spearheaded by the prominent law firm Robbins Geller Rudman & Dowd LLP, known for its extensive experience in securities litigation.

Background of the Case

The class action is officially titled Bridgewood v. MoonLake Immunotherapeutics, filed under case number 25-cv-08500 in the U.S. District Court for the Southern District of New York. Investors who have purchased or acquired MoonLake's common stock and suffered losses during the class period are eligible to participate. The deadline for lead plaintiff motions is set for December 15, 2025.

This lawsuit arises against the backdrop of MoonLake's flagship drug candidate, sonelokimab (referred to as SLK), developed for treating hidradenitis suppurativa (HS). The complaint underscores allegations that MoonLake and its executives misled investors about SLK's efficacy, particularly in comparison to BIMZELX, a competitor that has already earned FDA approval for a similar indication.

Key Allegations

According to the allegations, the defendants failed to disclose critical information that could have helped investors make informed decisions. The allegations state that SLK and BIMZELX target the same inflammatory cytokines, IL-17A and IL-17F. Moreover, the lawsuit argues that SLK's unique Nanobody structure did not confer a clinical advantage over BIMZELX's monoclonal antibody approach. Evidence suggests that the assumed increased tissue penetration of SLK did not translate into superior clinical efficacy.

A pivotal moment occurred on September 28, 2025, when the results of MoonLake's Phase 3 VELA program were disclosed, revealing that SLK did not exhibit competitive efficacy compared to BIMZELX. Following this revelation, the stock price plummeted nearly 90%, resulting in significant financial injuries for shareholders.

The Role of the Lead Plaintiff

The Private Securities Litigation Reform Act of 1995 allows individual investors with substantial financial interests to step forward as lead plaintiffs. The role of the lead plaintiff is crucial; they represent the interests of all the affected shareholders in the lawsuit and can select their legal representation. Importantly, investors' ability to benefit from any future financial recovery doesn't hinge on their role as the lead plaintiff.

About Robbins Geller

Robbins Geller Rudman & Dowd LLP is recognized as a leading law firm in the realm of investor protection and securities litigation. With a remarkable track record, the firm has achieved the most monetary relief for investors in recent years. In 2024 alone, they recovered over $2.5 billion for clients involved in various class action cases. The firm boasts a team of 200 attorneys across 10 offices, making it one of the largest plaintiffs' litigation firms globally. Noteworthy past successes include recovering a staggering $7.2 billion in the Enron Corp. Securities Litigation.

For those affected by this situation, it's prudent to stay informed about the developments in the MoonLake class action lawsuit and consider the legal options available. Interested parties can obtain more information or contact Robbins Geller directly for further assistance.

More details can be found on their website: Robbins Geller Lawsuit Information.

• ---